# US 2013/0296353 A1 · Crystalline pharmaceutically active ingredients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296353 A1
- Document ID: US20130296353A1
- Status: Published application
- Kind: A1
- Application number: 13/885,509
- Filed: 2011-11-16
- Published: 2013-11-07
- Earliest claimed: 2010-11-16
- Assignees: EGIS Gyogyszergyar Nyilvanosan Mukodo Reszvenytar- sasag
- Inventors: Imre Markovits; Ferenc Jurak; Gyorgyi Kovanyine Lax; Csaba Hamori; Balazs Havasi; Eva Sipos; Balazs Volk; Zsolt Runge; Krisztina Fodorne Kocsmar; Gyula Lukacs; Katalin Kataine Fadgyas; Monika Mezovari
- Web page: https://patentgrep.com/patent/US20130296353A1

## CPC

- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is related to crystalline forms of rosuvastatin zinc (2:1) salt. The polymorphs are suitable for use as pharmaceutically active ingredients in the treatment of the diseases of the lipid metabolism including hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis.

## Claims

### Claim 1

A crystalline Form V rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of Formula (I)
which has
X-ray diffraction lines measured by CuKα radiation at the following diffraction angle 2Θ (±0.2° 2Θ): 4.746 degrees;
or
X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 4.746 and 15.371 degrees;
or
a powder X-ray diffractogram of FIG. 1;
or
the following X-ray diffraction lines measured by the CuKα radiation:
2Θ [°]
d-value [Å]
Relative intensity [%]
4.764
18.5324
100.0
5.873
15.0352
20.9
8.941
9.8823
11.1
9.547
9.2561
12.5
10.960
8.0664
20.7
11.773
7.5111
19.0
12.224
7.2347
20.6
12.870
6.8733
8.8
13.118
6.7438
21.1
13.979
6.3303
13.9
14.401
6.1454
9.8
15.371
5.7599
61.6
15.997
5.5359
13.2
16.357
5.4148
10.4
16.852
5.2570
8.0
17.641
5.0235
6.9
17.995
4.9256
29.6
18.783
4.7206
5.8
19.394
4.5733
31.9
19.977
4.4411
9.2
20.741
4.2792
5.1
20.959
4.2352
4.6
21.700
4.0922
12.3
22.263
3.9899
17.5
22.736
3.9080
9.7
23.367
3.8038
14.9
23.659
3.7575
12.9
24.235
3.6695
29.8
24.716
3.5992
10.5
25.245
3.5250
19.3
26.034
3.4199
9.5
26.485
3.3627
8.0
27.028
3.2964
12.9
28.016
3.1824
8.3
28.667
3.1115
8.0
29.662
3.0093
8.6
30.967
2.8854
9.2
32.668
2.7390
6.9
33.032
2.7096
8.0
33.342
2.6851
7.2
33.989
2.6355
5.6
34.452
2.6011
6.8

### Claim 2 (depends on 1)

A crystalline Form V rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of the Formula (I) according to claim 1, which has X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 4.746 and 15.371 degrees.

### Claim 3 (depends on 1)

A crystalline Form V rosuvastatin zinc salt (2:1) according to claim 1 having the following X-ray diffraction lines measured by CuKα radiation:
2Θ [°]
d-value [Å]
Relative intensity [%]
4.764
18.5324
100.0
5.873
15.0352
20.9
8.941
9.8823
11.1
9.547
9.2561
12.5
10.960
8.0664
20.7
11.773
7.5111
19.0
12.224
7.2347
20.6
12.870
6.8733
8.8
13.118
6.7438
21.1
13.979
6.3303
13.9
14.401
6.1454
9.8
15.371
5.7599
61.6
15.997
5.5359
13.2
16.357
5.4148
10.4
16.852
5.2570
8.0
17.641
5.0235
6.9
17.995
4.9256
29.6
18.783
4.7206
5.8
19.394
4.5733
31.9
19.977
4.4411
9.2
20.741
4.2792
5.1
20.959
4.2352
4.6
21.700
4.0922
12.3
22.263
3.9899
17.5
22.736
3.9080
9.7
23.367
3.8038
14.9
23.659
3.7575
12.9
24.235
3.6695
29.8
24.716
3.5992
10.5
25.245
3.5250
19.3
26.034
3.4199
9.5
26.485
3.3627
8.0
27.028
3.2964
12.9
28.016
3.1824
8.3
28.667
3.1115
8.0
29.662
3.0093
8.6
30.967
2.8854
9.2
32.668
2.7390
6.9
33.032
2.7096
8.0
33.342
2.6851
7.2
33.989
2.6355
5.6
34.452
2.6011
6.8

### Claim 4 (depends on 1)

A rosuvastatin zinc (2:1) salt according to claim 1, having a powder X-ray diffractogram of FIG. 1 measured by CuKα radiation.

### Claim 5 (depends on 1)

A rosuvastatin zinc (2:1) salt according to claim 1, containing 1 to 10 moles of water.

### Claim 6 (depends on 1)

A mixture of crystalline rosuvastatin zinc (2:1) salt according to claim 1 and amorphous rosuvastatin zinc (2:1) salt.

### Claim 7 (depends on 1)

A method for preparing crystalline Form V rosuvastatin zinc (2:1) salt according to claim 1, comprising transforming amorphous rosuvastatin zinc (2:1) salt into crystalline Form III rosuvastatin zinc (2:1) salt, stirring the thus obtained product in 2 to 100-fold amount of water or in a mixture of water and an alcohol comprising 1 to 6 carbon atoms at a temperature between −10 and 40° C. for 1 to 168 hours, and isolating and optionally drying the product.

### Claim 8 (depends on 1)

A method for preparing crystalline Form V rosuvastatin zinc (2:1) salt of the Formula (I) according to claim 1, comprising stirring rosuvastatin zinc (2:1) salt crystalline Form III in 2 to 100-fold amount of water or in a mixture of water and an alcohol comprising 1 to 6 carbon atoms at a temperature between −10 and 40° C. for 1 to 168 hours, and isolating and optionally drying the product.

### Claim 9 (depends on 7)

A method according to claim 7, wherein the stirring, isolation and optional drying is carried out under an inert gas atmosphere.

### Claim 10 (depends on 7)

A method according to claim 7, wherein the drying is carried out at a temperature between 0 and 30° C.

### Claim 11 (depends on 1)

A pharmaceutical composition, comprising crystalline Form V rosuvastatin zinc (2:1) salt according to claim 1, and a pharmaceutically acceptable vehicle.

### Claim 12 (depends on 11)

A method for preparing a pharmaceutical composition according to claim 11, comprising mixing crystalline Form V rosuvastatin zinc salt with a pharmaceutically acceptable vehicle and transforming into a pharmaceutical dosage form.

### Claim 13 (depends on 1)

A method for therapy, comprising administering to a subject in need thereof an effective amount of a crystalline Form V rosuvastatin zinc salt (2:1) according to claim 1.

### Claim 14 (depends on 1)

A method for treating lipid metabolism, hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis, comprising administering to a subject in need thereof an effective amount of a crystalline Form V rosuvastatin zinc salt (2:1) according to claim 1.

### Claim 15 (depends on 1)

A method for treating a disorder in lipid metabolism, hypercholesterolemia, hyperlipidemia, dyslipidemia or atherosclerosis, comprising administering to a subject in need thereof an effective amount of a crystalline Form V rosuvastatin zinc salt (2:1) according to claim 1.

### Claim 16

(canceled)

### Claim 17

A crystalline Form III rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of Formula (I)
which has
X-ray diffraction line measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 18.961 degrees;
or
X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 13.414 and 18.961 degrees;
or
X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 10.982, 13.414, 16.401, 18.600, 18.961, 19.409, 20.462 and 22.302 degrees;
or
X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 9.400, 10.982, 13.414, 15.480, 16.401, 16.623, 16.926, 18.338, 18.600, 18.961, 19.409, 20.462, 21.846, 22.302, 22.779, 23.232, 26.451, 27.178, 27.603, 31.311 and 31.861 degrees;
or
a powder X-ray diffractogram of FIG. 2 measured by CuKα radiation;
or
characteristic reflexions in a powder X-ray diffractogram measured by CuKα radiation according to the following table:
Relative
Intensity
2Θ
d (Å)
(%)
6.259
14.11083
90.2
9.400
9.40131
36
10.982
8.04997
62.4
11.318
7.81202
15.4
12.565
7.03939
12.1
13.414
6.59524
92.8
14.437
6.13017
5.4
14.806
5.97820
19.6
15.48
5.71948
20.5
15.776
5.61288
18.7
16.059
5.51479
15.4
16.401
5.40024
50.1
16.623
5.32865
44.8
16.926
5.23406
43.6
17.572
5.04319
15.4
17.894
4.95294
15.4
18.338
4.83405
48.9
18.600
4.76648
50.4
18.961
4.67672
100
19.409
4.56959
58.2
20.462
4.33695
53.2
21.383
4.15201
12.6
21.846
4.06507
47.1
22.302
3.98297
58.1
22.779
3.90066
39.5
23.232
3.82568
35.6
24.055
3.69663
10.4
24.690
3.60288
17.4
25.388
3.50540
16.9
26.451
3.36697
33.9
27.178
3.27846
22.5
27.603
3.22900
20.6
28.472
3.13240
16.2
29.938
2.98221
14.8
30.180
2.95883
16.7
31.311
2.85449
21.8
31.861
2.80646
25.7
32.695
2.73674
14.6
33.177
2.39812
13.2
34.134
2.62459
8

### Claim 18 (depends on 17)

A crystalline Form III rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of the Formula (I) according to claim 17, which has X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 13.414 and 18.961 degrees.

### Claim 19 (depends on 17)

A crystalline Form III rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of the Formula (I) according to claim 17, which has X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 10.982, 13.414, 16.401, 18.600, 18.961, 19.409, 20.462 and 22.302 degrees.

### Claim 20 (depends on 17)

A crystalline Form III rosuvastatin zinc (2:1) salt [hemizinc salt of (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-(3R,5S)-dihydroxy-hept-6-enoic acid] of the Formula (I) according to claim 17, which has X-ray diffraction lines measured by CuKα radiation at the following diffraction angles 2Θ (±0.2° 2Θ): 6.259, 9.400, 10.982, 13.414, 15.480, 16.401, 16.623, 16.926, 18.338, 18.600, 18.961, 19.409, 20.462, 21.846, 22.302, 22.779, 23.232, 26.451, 27.178, 27.603, 31.311 and 31.861 degrees.

### Claim 21 (depends on 17)

A crystalline Form III rosuvastatin zinc (2:1) salt according to claim 17, which has a powder X-ray diffractogram of FIG. 2 measured by CuKα radiation.

### Claim 22 (depends on 17)

A crystalline Form III rosuvastatin zinc (2:1) salt according to claim 17, which has characteristic reflexions in a powder X-ray diffractogram measured by CuKα radiation according to the following table:
Relative
Intensity
2Θ
d (Å)
(%)
6.259
14.11083
90.2
9.400
9.40131
36
10.982
8.04997
62.4
11.318
7.81202
15.4
12.565
7.03939
12.1
13.414
6.59524
92.8
14.437
6.13017
5.4
14.806
5.97820
19.6
15.48
5.71948
20.5
15.776
5.61288
18.7
16.059
5.51479
15.4
16.401
5.40024
50.1
16.623
5.32865
44.8
16.926
5.23406
43.6
17.572
5.04319
15.4
17.894
4.95294
15.4
18.338
4.83405
48.9
18.600
4.76648
50.4
18.961
4.67672
100
19.409
4.56959
58.2
20.462
4.33695
53.2
21.383
4.15201
12.6
21.846
4.06507
47.1
22.302
3.98297
58.1
22.779
3.90066
39.5
23.232
3.82568
35.6
24.055
3.69663
10.4
24.690
3.60288
17.4
25.388
3.50540
16.9
26.451
3.36697
33.9
27.178
3.27846
22.5
27.603
3.22900
20.6
28.472
3.13240
16.2
29.938
2.98221
14.8
30.180
2.95883
16.7
31.311
2.85449
21.8
31.861
2.80646
25.7
32.695
2.73674
14.6
33.177
2.69812
13.2
34.134
2.62459
8

### Claim 23 (depends on 17)

A method for preparing crystalline Form III rosuvastatin zinc (2:1) salt according to claim 17, comprising stirring amorphous rosuvastatin zinc (2:1) salt at a temperature between −10 and 40° C. in 5 to 100-fold weight of water or in a mixture of water and an alcohol comprising 1 to 6 carbon atoms optionally containing 0.0001 to 0.01 molar equivalent amount of sodium hydroxide, calculated for the molar amount of rosuvastatin zinc salt of the Formula (I), for 1 to 48 hours, filtering the suspension, optionally repeating the stirring in 5 to 100-fold weight of water or in a mixture of water and an alcohol comprising 1 to 6 carbon atoms at a temperature between −10 and 40° C. for 1 to 48 hours, and optionally washing and drying the product.

### Claim 24 (depends on 17)

A method for preparing amorphous rosuvastatin zinc (2:1) salt according to claim 17, comprising providing a solution of rosuvastatin tert-butylamine salt in water or in a mixture of water and an alcohol comprising 1 to 6 carbon atoms, adding into said solution an aqueous solution of a zinc salt, at room temperature, and mixing and stirring said solution with 2 to 50-fold volume of water cooled to the temperature between −10 and 20° C.
